How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?

被引：5

作者：

Christoph Koenen

机构：

[1] Novo Nordisk A/S,

[2] Krogshøjvej 55,undefined

来源：

Nature Clinical Practice Endocrinology & Metabolism | 2008年 / 4卷 / 10期

关键词：

D O I：

10.1038/ncpendmet0972

中图分类号：

学科分类号：

摘要：

引用

页码：E1 / E1

共 6 条

[1]

Marks JB(2008)How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 4 490-491

[2]

Rosenstock J(2008)A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetologia 51 408-416

[3]

Klein O(2007)Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes Diabetes Obes Metab 9 290-299

[4]

Heise T(2007)Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies Diabetes Obes Metab 9 648-659

[5]

Pieber TR(2007)Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 23 441-454

[6]

DeVries JH(undefined)undefined undefined undefined undefined-undefined

← 1 →